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1. Introduction 
1.1 The changing scenario of food allergy   
Food allergy (FA) is an adverse health effect arising from a specific immune response that 
occurs reproducibly on exposure to a given food (1). It is one of the most common allergic 
disorders in the pediatric age, and it has been recognized as a global health problem, 
particularly in industrialized countries. Studies have suggested that the epidemiology of FA 
has changed during the last two decades, with a dramatic rise in the prevalence, severity of 
clinical manifestations, and risk of persistence into later ages, leading to an increase in 
hospital admissions, medical visits, treatments, burden of care on families and to an important 
economic impact, with significant direct costs for the families and healthcare system (2-4). In 
Europe, around 7 million of people suffer from challenge-proven FA. If this prevalence is 
projected onto the world’s population of 7 billion, it translates into 63 million-1.16 billion of 
potential food-allergic people, with a greater incidence in children (5-8%) than in adults (1-
2%) (5). Furthermore, about 8% of people suffering from FA are exposed to the risk of 
potentially life-threatening allergic reaction resulting in death, mainly amongst children aged 
0–14 years. According to the most recent epidemiological data, time trend analysis showed up 
to 7-fold increase in hospital admissions for food severe allergic reactions in children in the 
UK, USA, Italy and Australia over the last 10 years (6-10). Although more than 170 foods 
have been identified as triggers of FA, there is rather short list of foods account for most of 
the more serious disease burden, namely peanut, tree nuts, fish, shellfish, egg, milk, wheat, 
soy, and seeds, with national and geographical variations concerning the most common FA 
(1,11-16).  
 
1.2 New insights in the pathogenesis of food allergy  
FA derives from a breakdown of immune tolerance (17).  Induction and maintenance of 
tolerance to food antigens requires active generation of food antigens specific regulatory T 
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cells (Tregs), which are influenced by the resident microbiome (18,19). Current knowledge 
suggests that the epidemiology of FA might be influenced by genetics and genome-
environment interactions leading to immune-system dysfunction, mediated at least in part by 
epigenetic mechanisms (20,21). Many factors have been postulated to contribute to the onset 
of FA. Among the multiple immutable risk factors that could influence FA onset, there are the 
male sex, ethnicity (increased risk among Asian and black children compared with white 
children), and genetics (familial associations, HLA, and specific genes) (22-26). In addition, 
there are other risk factors that can be potentially addressed to reduce/prevent FA. These 
factors are related (mode of delivery, breast milk, use of acid-suppressive medications or 
antibiotics, use of antiseptic agents, rural environment, junk food-based and/or low fibers/high 
fat diet, consumption of unpasteurized milk or fermented foods, exposure to pets) or unrelated 
(comorbid atopic dermatitis, vitamin D insufficiency,  reduced consumption of omega-3-
polyunsaturated fatty acids or antioxidants, timing and route of exposure to foods) to an 
influence on gut microbiota development and function (27-30).  
1.3 Natural history of food allergy  
Many subjects with FA naturally outgrow it over time; however, the natural course highly 
depends on the causative allergen. Cow’s milk allergy (CMA), hen’s egg and wheat allergy 
approximately resolve in 50% of children by the age of 5-10 years. Other FAs (including 
peanut, tree nut, fish) have low rates of resolution or are considered persistent (31). In 
addition, many forms of FA, including CMA, may be associated with later development of 
other allergic diseases such as asthma, oculorhinitis, urticaria, and atopic dermatitis (the so 
called “Atopic March”) (32), as well as other diseases such as functional gastrointestinal 
disorders (FGIDs) (33), inflammatory bowel diseases (IBD) (34), and psychiatric disorders, 
such as attention deficit hyperactivity disorder (ADHD), autistic spectrum disorders (ASD) 
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and obsessive-compulsive disorder (OCD) (35). The pathogenesis of these events is still 
largely unknown, but increasing evidence suggest that perturbation of gut microbiota, leading 
to alterations in immune system and gut-brain axis, could influence the occurrence of FA and 
FA-related conditions later in the life (Figure 1).    
1.4 Gut microbiota features in food allergy: investigating the metagenomic and 
metabolomics features  
The knowledge and awareness of the role the gut microbiota and metabolites in the balance 
between health and disease is rapidly increasing. This is mainly due to the advance in 
technology and the availability we currently have of high sensitivity means to study microbial 
communities in any type of ecosystem. It is important for the clinicians and researchers 
dedicated to the FA field to know potential and limits of these technologies to better 
understand the value and significance of the findings reported in literature. Thanks to the 
power of genome DNA sequencing, we have learned much about the composition of gut 
microbial communities. In addition, the potential of transcriptomics, proteomics and 
metabolomics are enlarging our understanding of the gut microbiota role in human health. 
Until the 1990s, knowledge of the gut microbiota was limited because the only technique used 
to study and characterize the composition of gut microbiota was bacteriological culture.  
Since the 1990s, there were advances in culture-independent techniques. These new 
techniques are fast, facilitate high throughput, identify organisms that are uncultured to date 
and enable enumeration of organisms present in the gut microbiota. In the last decade, the 
composition of the gut microbiota was described by next generation sequencing of 16S 
ribosomal RNA genes. Lately, it is widening the amount of information that can be retrieved 
by studying metagenomes from human samples, with the capability to infer the abundance of 
genes and potential metabolic pathways that characterize a microbial community. It is 
possible to describe the taxonomic composition of the microbiota and also to study the 
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potential functions in a given system. Such methodological background is fundamental to 
investigate associations between microbiota structure and health as well as other 
environmental factors (36) and also to observe the changes of the gut microbiota in response 
to disease or perturbations in diet or lifestyle. An advanced technique to investigate gut 
microbiota at deep level is shotgun sequencing that represents a massive parallel sequencing 
of the whole genome. This is done by massive parallel sequencing of the mixed DNA sample. 
Shotgun sequencing involves random fragmentation of DNA, sequencing of DNA fragments 
and reconstruction of overlapping sequences to assemble them into a continuous sequence 
(37). Metabolomics represents one of the meta-omic approach to study gut microbiota 
function. Metabolomics uses high throughput techniques to characterize and quantify small 
molecules in several biological samples such as feces, urine, plasma, serum, saliva (38). The 
use of metabolomics is considered a powerful top-down systems biology approach, and it is 
essential to reveal the genetic-environment-health relationship, as well as the clinical 
biomarkers of diseases (39). Currently, the rapid development of several analytical platform, 
including Gas Chromatography Mass Spectrometry (GC- MS), liquid chromatography (LC), 
high pressure LC (HPLC), ultra pressure LC (UPLC), Fourier transform infrared spectroscopy 
(FTIR), ion cyclotrone resonance-FT (ICR-FT), capillary electrophoresis (CE) coupled to 
mass spectrometry (MS), and nuclear and proton nuclear magnetic resonance spectroscopy 
(NMR-1H-NMR), allowed to separate, detect, characterize and quantify metabolites and their 
metabolic pathways (40). What is needed is a transition from descriptive research to 
understanding the ways the microbiome interacts with the host and plays a role in health and 
disease. In this frame, controlled clinical interventions are of utmost importance to establish 
microbiota causative involvement and are the basis to implement approaches of personalized 
medicine (41,42). The study of the relationship between microbiota and FA may start from 
association and be translated to causation and clinical practice with appropriate advances in 
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knowledge. An initial wide screening of microbial diversity in gut microbiota of patients with 
a sure diagnosis of FA, including a well-matched control population, may identify useful 
signatures in the microbiota that are specific for certain types of FA (43,44). If the wide 
screening included cohorts of patients with different dietary style or ethnicity, the common 
microbial signatures would be even stronger and provide a solid indication of the microbial 
biomarkers of FA. A further mapping of the genomic features associated to FA maybe 
inferred by metagenomics and metabolomics, which may inform on the functional microbial 
signatures that can be recognized in FA patients. 
Biomarkers strains or defined microbial systems may be tested in gnotobiotic or humanized 
animal models to observe the development of the disease, and beneficial vs detrimental 
microbial metabolites can be recognized and used as final target of microbiome-targeted 
personalized interventions. The identification of bacterial metabolites, that affect positively 
the immune tolerance network, may be an interesting strategy against FA using a post-biotic 
approach. 
 
1.5 Evidence on gut microbiota dysbiosis in food allergy 
There is mounting evidence that the alterations of gut microbiota composition (dysbiosis) 
early in life play a key role in early host immunological development and represents a critical 
factor underlying FA and occurrence of other allergic and not allergic diseases later in the life 
(28,30,45,46). Many epidemiologic data suggest a link between environmental factors able to 
influence gut microbiota composition and function, and the occurrence of FA (Figure 2). But 
these data only support the notion that several factors potentially influencing gut microbiota 
may be key risk modifiers for the development of FA. Unfortunately, data characterizing the 
microbiota of patients with FA are still preliminary. Table 1 summarizes main evidences on 
FA-associated gut microbiota features. Heterogeneity in study design, including sampling 
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time points, methods used to characterize the gut microbiota, and different allergic 
phenotypes under study, make it difficult to establish a causal relation between specific 
bacterial taxa and development of FA. Despite these limitations at least 4 relevant 
observations on FA-associated gut microbiota can be raised: 
- Dysbiosis precedes the FA onset; 
- Microbial community structure early in life, in particular in the first 6 months of life, is 
more relevant in FA development;  
- No specific bacterial taxa could be consistently associated with FA onset, with a broad 
range of microbes that could have positive or negative influence on tolerogenic 
mechanisms;  
- Dysbiosis could influence not only the occurrence, but also the disease course of FA 
(46).  
 
1.6 Targeting gut microbiota in food allergy: the importance of the diet-gut microbiota 
axis  
Advances in metagenomics and metabolomics implicate diet and gut microbiota (the diet-gut 
microbota axis) as key modulators of the maturation of the immune system. Findings from a 
recent systematic review further support the relationship between maternal diet during 
pregnancy and lactation and allergic sensitization to food during childhood (47). Diet during 
the first 1000 days of life, from conception up to the first 24 months of age, may influence the 
risk of developing FA (48-50). A recent study examining the influence of dietary patterns on 
the development of FA at the age of 24 months suggests that a healthy child diet with high 
levels of fruits, vegetables, and home-made foods is associated with less FA (51).  
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The role of maternal and infant diet in the development of food allergy has been a major focus 
of research throughout this period. Allergen exposure can potentially occur in utero could 
impact on food allergy development. Early introduction of  peanut has been shown to be 
protective against the development of peanut allergy in high-risk children with the body of 
evidence suggesting the same is true for egg allergy (52). One cohort reported that the delayed  
introduction of rice/wheat cereal (>6 months of age) was associated with a lower risk of food 
allergy (53). In addition to allergenic food introduction, postnatal vitamin D status and 
prebiotic and/or probiotic supplementation has been suggested to be associated with the 
development of food allergy. Zhang et al. (54) recently performed a meta-analysis of 
randomized controlled trials about probiotic supplementation during pregnancy and/ or 
infancy and their effects on atopy in children. They found that administering probiotics 
prenatally to pregnant mothers and postnatally to the child both could reduce the risk of food 
sensitization. Based on a review of the literature, the World Allergy Organisation guideline 
panel suggests using prebiotic supplementation in infants who are not exclusively breastfed, 
but not for exclusively breastfed infants (55). 
Several studies reported that nutrients impact the gut microbiota and the bacterial metabolites 
production (56,57). The Mediterranean diet (MD) is highly regarded as a healthy balanced 
diet. It is characterized by high consumption of assorted fruits, vegetables, cereals, legumes, 
olive oil, and nuts; moderate consumption of fish, poultry, and red wine; and a lower intake of 
dairy products, red meat, processed meat and sweets.  It has been demonstrated that adherence 
to MD during pregnancy and early life has a protective effect on allergic disease in children 
(58). These effects could derive from the high intake of non-digestible dietary carbohydrates 
(NDC), the beneficial fatty acid profile that is rich in omega-3, the high levels of polyphenols 
and other antioxidants (59). Non-digestible dietary carbohydrates represent the primary 
nutrient source for the gut bacteria and their fermentation leads to the production of short 
12 
 
chain fatty acids (SCFA) (60). It has been demonstrated that reduced availability of NDC 
lowered the concentration of fiber-degrading bacteria and increased mucin degrading bacteria 
(61). De Filippis et al. observed a significant association between degree of adherence to the 
MD and increased levels of SCFAs, Prevotella bacteria, and other Firmicutes (62).  
The immunomodulatory mechanisms stimulated by SCFAs represent one of the strongest 
connections between diet, gut microbiota, and allergic diseases (63). SCFAs are 2-carbon to 
5-carbon weak acids, including acetate, propionate, butyrate and valerate (64). SCFAs-
producing bacteria represent a functional group, including Bacteroidetes phylum that are good 
producers of acetate and propionate, whereas Faecalibacterium prausnitzii, which belongs to 
the Clostridium leptum cluster (or clostridial cluster IV), and Eubacterium rectale/Roseburia 
spp., which belong to the Clostridium coccoides cluster (or clostridial cluster XIVa) of 
Firmicutes bacteria are efficient butyrate producers (65). SCFAs are major energy source for 
colonocytes and influence gene expression necessary for the expression of epithelial barrier-
forming molecules and mucin production defense functions and regulation of immune cells, 
such as macrophages, neutrophils, DCs, T and B-cells (66-72).  They are absorbed by 
colonocytes and other cells via transporters (SLC16a1 and SLC5a8), via simple diffusion or 
through G-protein coupled receptors (GPCRs), such as GPR43, GPR41, GPR109A and 
Olfr78 (73-76). GPR43 and GPR41 are highly expressed by intestinal epithelial cells (77). 
Neutrophils, macrophages and DCs, express GPR43 and GPR109A, but T- and B-cells do not 
express these SCFA receptors (78-82). 
Among SCFAs, butyrate exerts a pivotal role in immune tolerance induction. It is able to 
regulate DCs, reducing pro-inflammatory cytokines and chemokines production and 
enhancing retinoic acid (RA) expression and subsequent generation of RA-regulated 
tolerogenic DCs (83).  
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It has been found that SCFA individually or in combination (SCFA mix) are able to increase 
colonic Treg frequency and number and that this effect coincide with increased luminal 
SCFA. Furthermore, SCFA are able to increase also CD4+ T cell frequency and number but 
did not alter colonic Th1 or Th17 cell numbers (84). In vitro treatment of colonic Tregs from 
germ free mice with propionate significantly increased FoxP3 and IL-10 expression, a key 
cytokine in Treg-mediated suppression suggesting that SCFA specifically induce FoxP3+ IL-
10-producing Tregs (85). In a mouse model, it has been demonstrate that butyrate, facilitated 
generation of colonic Treg cells, acting as to HDAC-inhibitory and enhance acetylation of the 
Foxp3 locus, induced a decrease of  proinflammatory cytokine expression within DCs to 
stimulate colonic Tregs (86). 
The mechanisms are multiple and involve a strong epigenetic regulation of gene expression 
through the inhibition of histone deacetylase (HDAC). Butyrate promoting B-cell 
differentiation and increasing IgA and IgG production through their HDAC inhibitory activity 
(87). It has been demonstrated that butyrate suppresses CD4+ T-cell proliferation and increase 
colonic FoxP3+ Tregs, potentially through their HDAC inhibitor activity (88-90). The 
inhibition of HDAC 9 and 6 increases FoxP3 gene expression, as well as the production and 
suppressive function of Tregs (91). 
Butyrate deficiency has been observed in allergic patients (92). Bacteria-produced SCFAs 
have been implicated in the regulation of both the proportions and functional capabilities of 
Tregs, which, in some studies, has been specifically attributed to butyrate production by 
spore-forming Clostridiales. It has been observed an enrichment of taxa from the Clostridia 
class and Firmicutes phylum in human subjects with faster CMA resolution (92). Altogether 
these evidences suggest the potential of a “post-biotic” approach, based on the use of butyrate 
against FA. In this light, data from our laboratory showed that oral butyrate induces a 
dramatic inhibition of acute allergic skin response, anaphylactic symptom score, body 
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temperature decrease, intestinal permeability increase, anti-β lactoglobulin (BLG) IgE, IL-4 
and IL-10 production in a murine model of CMA, suggesting a protective role of butyrate 
against FA (93). We evaluated the direct effects of butyrate on peripheral blood mononuclear 
cells (PBMCs) from children affected by challenge-proven IgE-mediated CMA. PBMCs were 
stimulated with BLG in the presence or absence of butyrate. Preliminary results showed that 
butyrate stimulates IL-10 and IFN-γ production and decreases DNA methylation rate of these 
two cytokines. Same effective butyrate dose induces FoxP3 promoter region demethylation 
and HDAC6/HDAC9 expression down-regulation (93,94). 
Additional potential mechanisms by which diet could exert pro-tolerogenic effects in the gut 
are related to the production of immunoregulatory metabolites, which interact with the host 
immune cells to promote non-responsiveness to innocuous luminal antigens (95). Tryptophan 
is essential amino acid which cannot be synthesized independently by humans, thus, need to 
be ingested with the diet. A part of tryptophan is utilized to synthesize protein, the other 
portion is catabolized to produce variety bioactive compounds, such as kynurenine, serotonin, 
melatonin. Tryptophan absorbed by intestinal epithelial cells directly activates the mTOR 
pathway by intracellular tryptophan receptors through a PI3K/AKT-independent mechanism 
(96,97). As we known, mTOR plays an important role in connecting metabolism and immune 
system. During an inflammatory process, tryptophan is metabolized through the kynurenine 
(Kyn) pathway. Kyn is an active metabolite and its biological activity is mediated by aryl 
hydrocarbon receptor (AhR) (98). The bond of Kyn to AhR receptor (99) lead to the 
inhibition of dendritic cells (DCs) maturation (100) and the proliferation of Th17 cells and 
Treg, increasing IL-22 and IL-10 production (101,102). Indole, indole 3-propionic acid (IPA) 
and indole-3-aldehyde (I3A) are produced by catabolism of tryptophan through intestinal 
commensal bacteria. A study demonstrated that Peptostreptococcus anaerobius CC14N and 
three strains of Clostridium cadaveris utilizing tryptophan to produce IPA. Another study 
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suggested that IPA could promote the intestinal barrier function via PXR and TLR4 pathway. 
Tryptophan can be also catabolized by lactobacilli to I3A. This metabolite protects gut 
mucosa against inflammation through AhR recognition (103). 
It has been demonstrated that indole-3-carbinole (I3C), an AhR ligand, was able to boost oral 
tolerance in ovalbumin (OVA)-sensitized mouse model. Mice fed I3C showed lower titers of 
anti-OVA IgG1 antibodies and higher number of CD103+MHC-II+ tolerogenic DCs compared 
to normal chow-fed control mice (104).  
 
1.7 The role of breastfeeding in food allergy 
Breastfeeding has important health benefits for infants and represents the gold standard of 
nutrition for infants (105).  However, the role of human milk (HM) in the primary prevention 
of FA (10) are still undefined. One birth cohort from Taiwan reported exclusive or partial 
breastfeeding for 6 months was associated with reduced milk sensitization at ages 1 and 1.5 
years compared with formula feeding (106). An influence of breast milk on the development 
of disease in offspring may also be explained by the composition of breast milk. Mothers’ diet 
during lactation can alter the composition of breast milk, which might have an impact on 
allergic outcomes. A small cohort study (FARMFLORA) in Sweden showed mothers 
consuming more margarine, margarine and oils and low-fat milk during pregnancy and were 
more likely to have pediatrician-confirmed allergic children (107). HM is a complex living 
nutritional fluid that contains antibodies, enzymes, and hormones, all of which have health 
benefits (108). It has been demonstrated a pivotal role of breast-milk antibodies for the 
development immature immune system of a newborn (109). Breast-milk antibodies that 
transfer in the newborn’s gut can help to determine the composition of microbes that colonize 
the intestine, and thereby prevent excessive immune responses to non-pathogenic microbes 
(109,110). Yet despite this maternally provided immune protection, an infant still faces an 
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extremely sensitive period in early life when the progressive microbial colonization of 
internal and external body surfaces occurs concurrently with the development and maturation 
of the immune system (111). In addition to passive immunity (from bioactive components 
such as secretory IgA and IgG), human milk also contains factors that actively stimulate the 
infant immune system (112). Accumulated data suggests that a wide range of bioactive 
factors: such as proteins, polyunsaturated fatty acids, oligosaccharides, microbial content, 
metabolites, lipids and micronutrients present in HM can influence the infant’s gut immune 
maturation (113). Milk lipids is the main source to supply energy for newborns such that it 
comprises ~50% of the energy that they need  (114). Milk lipids provide essential nutrients, 
which are needed, as structural elements, for all cell membranes and, as integral constituents 
of neural tissues, for rapidly growing infants (115-117). Among fatty acids, human milk has 
been examined as a potential source of the major SCFAs butyrate for neonates, with a 
different content of SCFAs than infant formula (118). However, butyrate levels in HM are not 
well established.   
 
1.8 Engineering gut microbiota with probiotics in food allergy 
Immune tolerance is a major therapeutic target in FA. Evidence support the concept that 
probiotics,  defined as live microorganisms which when ingested in adequate amounts confer 
a beneficial effect on the host (119), could act at different level on immune tolerance network 
in FA: modulating gut microbiota composition and function (increased production of 
butyrate) (43); interacting with enterocytes with subsequent modulation of non-immune (gut 
permeability and mucus thickness) (120-123) and immune tolerogenic mechanisms 
(stimulation of sIgA and -defensins production) (124);  modulation of cytokines response by 
immune cells (125-128). Main pre-clinical evidence on the probiotics activity against FA are 
summarized in Table 2. In the last decades, a number of experimental investigations have 
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been developed in order to characterize those organisms could be used to modulate the gut 
microbiota for FA. Stimulation of human peripheral blood mononuclear cells (PBMCs) with 
selected probiotic strains is a commonly used experimental tool for the investigation of the 
effect of these microorganisms on immune cells. The incubation of PBMCs with 
lactic acid bacteria (LAB) strains (such as L.plantarum and B.adolescentis) resulted in an 
increased production of the regulatory cytokine IL-10 by monocytes and dendritic cells, and 
to an enhance of IFN-γ production by T cells (129-131). The addition of probiotics mixture 
(L.acidophilus W55, L.casei W56, L.salivarius W57, L.lactis W58, B infantis W52, B.lactis 
W18 and B.longum W51) to PBMCs from children with FA resulted in increased T cell 
proliferation with enhanced production of Th1 and regulatory cytokines. An increase in T and 
B cells proliferation and a reduction in IgE production were also observed in PBMCs from 
children with FA treated for 3 months with the same probiotic mixture (132). Using a 3D co-
culture model of intestinal epithelial cells and PBMCs as an in vitro model of the intestinal 
mucosal immune system, Ghadimi et al demonstrated that the probiotics B.breve and 
L.rhamnosus GG (LGG) inhibit activation of inflammatory IL-23 and IL-17 cytokines, 
thereby reducing histone acetylation and simultaneously enhancing DNA methylation (133). 
The limitation of studying the effect of probiotics in vitro lies in the extrapolation of the 
results to in vivo benefits. For that reason, another commonly used experimental tool in this 
area is based on the use of animal model of FA.  Differential effects in relation to molecular 
action of oral administration of three LAB strains (B. coagulans 09.712, L.plantarum 08.923 
and B.infantis 11.322) in alleviating Th2-driven intestinal inflammation and other symptoms 
associated with food-induced anaphylaxis were demonstrated in a murine model induced by a 
major shrimp allergen, ST. In particular, oral supplementation with B.coagulans 09.712 and 
L.plantarum 08.923  significantly ameliorates anaphylaxis symptoms and increases the 
population of CD4+ CD25+FoxP3+ T cells in ST-sensitized mice through mTORC inhibition,  
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FoxP3 up-regulation and GATA-3 down-regulation (134). Zang et al investigated the 
preventive and therapeutic effects of oral C.butyricum on anaphylactic symptoms in FA mice 
model induced by a β -lactoglobulin (BLG) as allergen, a well-established model of CMA. 
The authors observed that the oral treatment with C.butyricum significantly ameliorated 
anaphylaxis symptoms and increased sIgA and CD4+ CD25+ FoxP3+Treg cell in spleen from 
BLG-sensitized mice (135). Neonatal monocolonization of germ-free mice by L.casei BL23 
modulated the allergic sensitization to cow’s milk proteins, developed higher IgG responses 
against caseins, elicited by L.casei that was able to hydrolyze insoluble caseins into soluble 
immunogenic peptides (136). Using OVA-sensitized murine model, it was demonstrated that 
oral administration of B.infantis ameliorated allergic symptoms, reducing OVA specific-IgE, 
and -IgG1 levels in the serum, and Th2 cytokines release in spleen. Moreover, gut microbiota 
analysis showed that the probiotics-mediated protection was conferred by up-regulation of the 
relative abundance of Coprococcus and Rikenella at genus level (137). Similar results was 
obtained by others that observed a decrease of concentrations of IgE, IL-4 and IL-13 
following administration of B.infantis CGMCC313-2 in BLG-sensitized mice (138). Oral 
administration of VSL#3 (a mixture of Streptococcus thermophilus BT01, B. breve 
BB02, B.longum BL03, B.infantis BI04, L.acidophilus BA05, L.plantarum BP06, L.paracasei 
BP07, L.delbrueckii subsp. bulgaricus BD08) to sensitized mice significantly reduces Th2 
immune responses and protects against anaphylactic reactions in a mouse model of FA. Also 
the incubation of mouse spleen cells from sensitized mice with probiotic mixture reduced 
allergen-stimulated IL-5 and IL-13 production and increased of IFN-γ and IL-10 production 
(139). An immunoregulatory action by LGG has been demonstrated in a murine model of 
CMA. LGG administration was able to suppress of Th2 responses such as reduced 
hypersensitivity scores and lowered serum CMP-specific IgG1 while promoting Th1 
responses by causing elevated IFN-γ and CMP-specific IgG2a levels (140). Similar results 
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have been reported by our group in a BLG-sensitized mice model, in which we found that the 
administration of LGG added to the extensively hydrolyzed casein formula (EHCF) elicited a 
significantly reduction of allergic reaction, and of IL-4, IL-5, IL-13 and specific IgE 
production (141). Clinical studies have investigated the efficacy of selected probiotic strains 
against FA. The effect appears strain-specific and more evident in the pediatric age. In a 
randomized double-blind placebo-controlled trial, it has been demonstrated that the 
administration of  L.casei CRL431 and B.lactis BB12 added to hypoallergenic formula for 
12 months did not affect the acquisition of immune tolerance to cow’s milk proteins in infants 
with CMA (142). Whereas, using a similar study design we have demonstrated that the 
addition of the probiotic LGG to EHCF is able to accelerate immune tolerance acquisition in 
infants with CMA. Infants (aged 1–12 months), consecutively referred for suspected CMA 
(IgE- or non-IgE-mediated), but still receiving cow’s milk proteins, were invited to participate 
in the study. Subjects were randomly allocated to one of the two groups of dietary 
interventions: control group, received an EHCF; and active group, received an EHCF 
containing LGG (at least 1.4×107 CFU/100 mL). After 12 months, the double-blind placebo-
controlled food challenge was negative in 15 of 28 control infants (53.6%) and in 22 of 27 
infants receiving EHCF with LGG (81.5%, p = 0.027) (143). The results were confirmed in a 
subsequent trial, when the effect of 5 different dietary strategies was investigated: EHCF, 
EHCF + LGG, partially hydrolyzed rice formula, soy formula or amino acid-based formula, in 
children affected by IgE- or non-IgE-mediated CMA. After the treatment period of 12 
months, the proportion of children acquiring immune tolerance to cow’s milk proteins was 
significantly higher in the group receiving EHCF+ LGG (78.9%) than in other groups (144). 
At the 3-year follow-up of another pediatric cohort, a further confirmation of a greater rate of 
resolution of IgE-mediated CMA as well as a lower incidence of other atopic manifestations 
was described after treatment with EHCF+LGG (145). These effects could derive at least in 
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part by a modulation elicited by selected LGG components on immune functions through 
different pathways including enterocytes, monocytes, mast cells, DCs and Tregs (146-149), 
and by an expansion of butyrate-producing gut microbiota (43). Accordingly, studies in 
infants with eczema and/or CMA who received EHCF supplemented with LGG showed 
benefits in decreasing gastrointestinal symptoms and inflammation (107,150). Probiotics has 
been also proposed to reinforce the effectiveness of immunotherapy (151). Oral food 
immunotherapy (OIT) is currently the most investigated approach for persistent FA and it is 
based on the concept that repeated oral/intestinal exposures to antigens normally leads to 
tolerance.  Tang et al. performed a randomized double-blind placebo-controlled trial with the 
probiotic L.rhamnosus CGMCC 1.3724 and peanut OIT (PPOIT) in 62 children with peanut 
allergy. Subjects received a fixed dose of probiotic (or placebo) together with peanut OIT (or 
placebo) once daily for a total of 18 months. Sustained unresponsiveness (SU), determined by 
DBPCFC conducted 2 to 5 weeks after discontinuation of treatment, was achieved in 82.1% 
of patients receiving PPOIT compared with 3.6% of those receiving placebo, the highest rate 
of SU reported for any food immunotherapy treatment evaluated in a randomized controlled 
study to date. PPOIT also induced high rates of desensitization (90%) and was associated with 
reduced peanut skin test reactivity, decreased peanut-specific IgE, and increased peanut-
specific IgG4 levels. PPOIT was well tolerated with no participants withdrawing because of 
adverse reactions (6 participants withdrew for reasons unrelated to PPOIT treatment); this is 
in stark contrast to OIT whereby 10% to 30% of participants withdraw because of adverse 
reactions. At approximately 4 years after the study ended, 67% were still consuming peanut, 
and only 58% of the 12 participants who stopped peanut ingestion for 8 weeks demonstrated 
sustained unresponsiveness. Importantly, no OIT control group was evaluated to determine if 
the probiotic itself had any effect on SU (152). Further studies comparing peanut OIT with 
probiotic with peanut OIT with placebo will be required to evaluate this strategy further. 
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1.9  Epigenetics regulation of food allergy  
Epigenetic modifications are biochemical changes of the chromatin, in other words, DNA or 
histones, that are functionally relevant, but do not affect the nucleotide sequence of the 
genome. DNA methylation, a covalent addition of a methyl group, occurs at the cytosine 
nucleotide belonging to CpG dinucleotide (called ‘CpG site’), which is a DNA sequence 
where a cytosine nucleotide (C) is directly followed by a guanine nucleotide (G). CpG sites 
frequently cluster to form ‘CpG islands’, typically located in the elements of a gene 
regulatory element with impact on its transcription, for example, promoters or enhancers 
(153,154). High DNA methylation levels in the CpG island of a promoter are usually 
associated with lower gene expression up to full gene silencing. The reaction of DNA 
methylation is catalyzed by DNA methyltransferases (DNMTs), including DNMT1 and 
DNMT3A and DNMT3B (156-159). The best-characterized post-translational histone 
modifications include phosphorylation, ubiquitination, acetylation and methylation, the last 
two of which are the most extensively studied (160,161). Histone acetylation occurs at the 
lysine residues and it is catalyzed by histone acetyltransferases, while the opposite reaction by 
histone deacetylases (HDACs). Histone acetylation independent of the position of the lysine 
amino acid generally correlates with potentially active genes or gene regulatory elements 
(162,163). DNA methylation and histone modifications mutually interact (164). MicroRNAs 
(miRNAs)  represent post-transcriptional control elements, important epigenetic regulators of 
gene expression (165;166). These approximately 22-nt noncoding RNA molecules are highly 
abundant, with more than 2500 mature miRNA molecules characterized in humans. To exert 
its function, mature miRNAs become incorporated into the RNA-induced silencing complex. 
The RNA-induced silencing complex is in turn guided by miRNAs to specifically target 
mRNAs. This leads to the cleavage or degradation of the bound mRNA molecule or 
suppression of its translation by reducing the speed of the ribosomal machinery (165-170). 
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Considering their biological importance, miRNAs have been involved in multiple human 
pathologies (167). These include also allergic diseases, in which the role of miRNAs has been 
rather extensively studied (171-175). It is also worth mentioning that the mechanism of RNA-
mediated silencing of gene expression has been utilized in biomedical research as a powerful 
laboratory tool (176) and in therapeutic applications as one of the possible antisense 
approaches (177). Connections between miRNAs and DNA methylation/histone 
modifications have also been described (165,167,169,170, 178). Several studies provide direct 
evidence linking epigenetics and FA (179-184). Martino et al. investigated whether variation 
in DNA methylation underscores the suboptimal neonatal CD4+ T-cell gene expression 
associated with the development of FA (179), including impaired T-cell expansion and 
reduced IFN- γ production (185-188). In a follow-up study, it was examined the genome-wide 
DNA methylation profiles in CD4+ T-cells from 12 children with FA and from 12 non-
allergic controls at birth and again at 12 months. The authors found that the dysregulation of 
DNA methylation at MAPK signaling-associated genes during early CD4+ T-cell 
development may contribute to T lymphocyte responses in early childhood associated with 
the development of FA (179). Further linking epigenetics and FA, the first genome-wide 
association study (GWAS) of FA in 2759 US participants revealed the important role of 
differential DNA methylation in mediating identified genetic risk factors for peanut allergies. 
(189). Syed et al demonstrated that subjects who acquired immune tolerance to peanuts after 3 
months of immunotherapy had higher numbers of Tregs with higher levels of FoxP3 
demethylation, compared to non-tolerant and healthy subjects (180). Recent study 
demonstrated that naive CD4+T cells from children with FA exhibit an intrinsic molecular 
defect during the early state of priming and depressed capacity for proliferation, which is 
related to epigenetic changes in metabolic (RPTOR, PIK3D, MAPK1, FOXO1) and 
immunological genes (IL1R, IL18RAP, CD82). Furthermore, the authors found that children 
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who fail to resolve FA in later childhood exhibit cumulative increases in epigenetic disruption 
at T cell activation genes and a decrease of CD4+ T cells proliferative responses compared to 
children who resolved FA (190). Preliminary cross-sectional studies have suggested that 
Th1/Th2 cytokine genes DNA methylation pattern and selected miRNAs expression change 
significantly during CMA disease course (182-184). In particular, we demonstrated a 
potential role of  miR-193a-5p in regulation of Th2 response in children with IgE-mediated 
CMA (184). Different demethylation rates in Treg-specific-demethylation region (TSDR) of 
FoxP3 have been also demonstrated comparing CMA children with active disease with those 
with recent evidence of immune tolerance acquisition (183). Dietary factors exert a pivotal 
role in the regulation of epigenetic mechanisms (191). Previous observations suggest that 
formula choice for CMA treatment could influence these mechanisms. Specifically, we 
observed a significant difference in DNA demethylation rate in TSDR of FoxP3, and in the 
promoter region of T helper (Th)1/Th2 cytokine genes in children who acquired immune 
tolerance after treatment with extensively hydrolyzed casein formula containing the probiotic 
Lactobacillus rhamnosus GG (EHCF+LGG) compared to subjects who received other 
formulas (182-184).  
The study of epigenetics in FA is a promising avenue that may lead to a better understanding 
of the mechanisms underlying FA etiology. It has been shown that both genetics and 
environmental factors can alter epigenetic profile (192-193). Thus, epigenetics may be the 
missing piece to understanding environmental–genetic interactions and FA risk. 
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2. Aim 
The aim of our study was to evaluate butyrate concentrations in HM and to see whether these 
butyrate concentrations can exert protective actions against FA, exploring several immune 
and non-immune tolerogenic mechanisms in different experimental models: 
1. CD4+ T cells from healthy controls and children with IgE-mediated FA  
2.  human enterocytes cell lines, HT-29 and Caco-2 
3.  mouse model of FA 
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3. Materials and Methods 
3.1 Donors and collection of human milk samples 
Mothers who participated in the study were enrolled after full-term, singleton births, with all 
mothers intending to breastfeed infants for at least 75% of feedings for 3 months from the 
Villa Betania Evangelic Hospital (Naples, Italy) in accordance with the Research Ethics 
Committee of the University of Naples “Federico II”. All donors were healthy, aged 21-42 
years and HM samples were donated at 3 days (colostrum) and during the first 5 months post-
partum. Written informed consent was obtained from all participants. HM samples were 
collected by either manual or electric breast pump expression into 2 mL a sterile milk tubes. 
Samples were immediately frozen and then stored at −80°C. For each enrolled subject, 
anamnestic, demographic, clinical and laboratory data were recorded in a data collection 
sheet. 3-days dietary diary before the collection of HM samples was obtained. The sampling 
procedures applied ensured that breastfeeding had been well established and that the baby was 
thriving. 
 
3.2 Determination of butyrate concentration in human milk samples 
Butyrate extraction from HM was performed as previously described (Clinica Chimica Acta, 
78 (1977) 243-250 Pretreatment methods prior to gaschromatographic analysis of volatile 
fatty acids from faecal samples J.B.Zijlstra, J.Beukema, B.G.Wolthers, B.M.Byrne, A.Groen, 
J.D.Anker). 0.5 ml  of  HM  were acidified with 20 μl of 85% (w/v) ortophosphoric acid and 
0.5 ml of ethyl acetate, mixed, centrifuged (12,000 x g) for 1 h and extracted in duplicate. 
About 0.5 ml of extract containing 3mmol/L of 2-ethylbutyric acid (internal standard) was 
transferred into a 2 ml glass vial and loaded onto an Agilent Technologies (Santa Clara, CA, 
USA) 7890 gas chromatograph (GC) system with automatic loader/injector. The GC column 
was an Agilent J&W DB-FFAP (Agilent Technologies) of 30 m, internal diameter 0.25 mm 
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and film thickness 0.25 μm. The GC was programmed to achieve the following run 
parameters: initial temperature 90°C, hold 0.5 min, ramp of 20°C min−1 up to a final 
temperature of 190°C, total run time 8.0 min, gas flow 7.7 ml min−1 split less to maintain 
3.26 p.s.i. column head pressure, septum purge 2.0 ml min−1. Detection was achieved using a 
flame ionization detector. Peaks were identified using a mixed external standard and 
quantified by peak height/internal standard ratio. 
 
3.3  Peripheral blood mononuclear cells stimulation and measurement of IL-4, IL-5, IL-
13, IL-10, and IFN-γ culture media concentration 
Two healthy children (Caucasian male, age 24 months with negative clinical history for any 
allergic conditions and not at risk for atopic disorders), referred to the Pediatric Department of 
the University of Naples “Federico II” because of minimal surgical procedure, and six 
children with challenge-proven FA (2 cow’s milk allergy, 2 peanut allergy, 2 egg allergy; all 
Caucasian male, age 24 months) were recruited. Patients and control subjects donated a 
venous blood samples in heparin tubes (8 ml), after written informed consents.  Peripheral 
blood mononuclear cells (PBMCs) were isolated using the Ficoll-Paque (Sigma-Aldrich, St. 
Louis, MO, USA) method, as described previously (183). PBMCs cells were stimulated with 
beta-lactoglobulin (BLG;100μg/ml), peanut extract (PN;100μg/ml) or ovalbumin 
(OVA;100μg/ml) in the presence or absence sodium butyrate (Sigma-Aldrich, Darmstadt, 
Germany) at dose of 0.75mM for 24h. After stimulation, the supernatants were collected and 
the cells were washed and harvested for CD4+T cells isolation. The concentrations of IL-4 
and IL-10 were measured in supernatants with a Human IL4/IL10 Enzyme immunoassay kit 
(Boster Biological Technology, Ltd., Fremont, CA, USA) according to the type of stimulation 
and stimulant. Human IL-5, IL-13 and IFN-γ ELISA, High Sensitivity (BioVendor, Brno, 
Czech Republic) were used to detect the IL-5, IL-13 and IFN-γ concentrations. Absorbance 
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was read at 450 nm. The minimum detection concentrations were 15.6 pg/ml for IL-4, 7.8 
pg/ml for IL-5, and IL-10, 1.6 pg/ml for IL-13, and 0.78 pg/ml for IFN-γ. 
 
3.4 DNA and RNA extraction from CD4+ T-cells  
CD4+ T-cells were obtained by negative selection using the CD4+ T-Cell Isolation Kit II 
(Miltenyi Biotec, Bergisch Gladbach, Germany) from stimulated PBMCs. Non-target cells 
were labeled with a cocktail of biotin-conjugated monoclonal antibodies (MicroBead 
Cocktail, Miltenyic Biotec) and the magnetically labeled non-target T cells were retaining on 
a column in the magnetic field of a separator (Miltenyi Biotec). This protocol produces >95% 
pure CD4+ T cells, as tested by fluorescence-activated cell sorting analysis. Cells were 
resuspended at 2x106 cells/ml in RPMI-1640 cultur medium (Gibco) supplemented with 10% 
fetal bovine serum, penicillin/streptomycin (1%) (Lonza), L-glutamine (1%), sodium pyruvate 
(1%) (Lonza) and NEAA (1%) (Lonza). Cells were cultured at 37°C in complete medium at 
concentrations of 2x105cells/ml in 24-well plate (Nunc, Roskilde, Denmark). CD4+ T-cells 
obtained were processed for DNA and RNA extraction. All experiments were performed in 
triplicate and repeated twice. 
 
3.5 DNA methylation analysis 
One microgram of DNA, extracted from CD4+T cells, was modified with sodium bisulfite to 
convert all unmethylated, but not methylated-cytosines to uracil. Bisulfite conversion was 
carried out using the EZ DNA Methylation Gold Kit (ZYMO Research Co., Orange, CA, 
USA), according to the manufacturer’s instructions. The converted DNA was stored at −20°C 
until used. Fully methylated and fully unmethylated DNA (Merck Millipore, Darmstadt, 
Germany) were used as controls for the optimization of the assay conditions and to calculate 
the percent of methylation (0% to 100%). The primers used for DNA methylation analysis of 
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IL-4, IL-5, IL-13, IL-10, IFN-gamma and FoxP3 TSDR are reported elsewhere (182,183). 
High-resolution melting real-time PCR for methylation analysis was performed as described 
previously (182,183). The results of methylation analysis were verified by direct sequencing 
(using the Sanger method modified as follows: ddNTPs labeled with four different 
fluorophores) and analyzed by capillary electrophoresis (the analytical specificity and 
sensitivity of the test was >99 %). Real-time PCR was performed with the LightCycler® 480 
instrument (Roche Applied Science, Penzberg, Germany) using 96-well plates (Roche 
Applied Science). 
 
3.6 Human enterocytes cell line  
Human enterocytes cell line Caco-2 and HT-29 were used (American Type Culture 
Collection, Teddington, Middlesex TW11 0LY, UK). Caco-2 cells were grown to confluence 
in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Berlin, Germany) supplemented 
with 10% fetal calf serum (Lonza, Visp, Switzerland), 1% L-glutamine (Lonza), 1% 
nonessential amino acids, and 1% penicillin/streptomycin (Lonza). HT-29 cells were grown to 
confluence in RPMI medium 1640 (Gibco, Berlin, Germany) supplemented with 10% fetal 
calf serum (Lonza, Visp, Switzerland) 1% L-glutamine (Lonza) and 1% 
penicillin/streptomycin (Lonza). Cells were cultured at 37°C in a water-saturated atmosphere 
consisting of 95% air and 5% CO2, and the medium was changed every 2 days.  All 
experiments were performed in triplicate and repeated twice. 
 
3.7 Immune and non-immune biomarkers analysis on human enterocytes 
At full confluence (15 days), when a human enterocytes monolayer was obtained from Caco-2 
and HT-29 in six-well plates (Falcon, Heidelberg, Germany), cells were stimulated for 48h 
with or without sodium butyrate at different doses (0.1; 0.5; 0.75; 1; 2 mM). Afterward, the 
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supernatants were harvested and stored at −80°C for further use. Cells were used for RNA 
extraction to perform real-time PCR experiments. The concentration of  β-defensin 3 (HBD-
3) in the supernatants was measured using a commercially available ELISA kit specific for 
human HBD-3 (MyBioSource,  San Diego, CA, USA) with a detection limit of 11.3 pg/ml. 
The ELISA was conducted according to the manufacturer’s recommendations.  For ZO-1, 
Occludin, Muc2 and Muc5AC and FoxP3 expression analysis, total cellular RNA was 
extracted from cells with TRIzol reagent (Gibco BRL, Paisley, Scotland). RNA (1 μg) was 
reverse transcribed at 37°C in cDNA with a High-Capacity RNA-to-cDNA™ Kit (Life 
Technologies, Waltham, MA, USA) according to the manufacturer’s instructions. 
Complementary DNA (cDNA) was stored at −20°C until use. Quantitative real-time PCR 
(qRT-PCR) analysis was performed with the TaqMan miRNA assay kit and the TaqMan gene 
expression assay kit, respectively (both from Applied Biosystems, Grand Island, NY, USA) 
according to the manufacturer’s instructions. Samples were run in duplicate at 95°C for 15 
seconds and 60°C for 1 minute using an ABI Prism 7900 HT Sequence Detection System 
(Applied Biosystems). After a hot start, the amplification protocol was 40 cycles of 30 sec of 
denaturation at 95°C, 30 sec of annealing at 60°C, and 1 min of elongation at 72°C. Data 
analysis was performed with the comparative threshold cycle (CT) method. We used the 
GAPDH gene to normalize the level of mRNA expression.  
For measurement of the mucus thickness, human enterocytes cell lines were seeded onto 
polycarbonate membranes (0.4 μm pore size) from TranswellTM (Corning Inc., New York, 
US) at 37°C in an atmosphere with 95% humidity and 5% CO2. At full confluence (14 days), 
the cells were stimulated for 24, 48 and 72 h with or without butyrate. A pair of membranes 
cultured under the same conditions were embedded immediately in an optimal cutting 
temperature compound (BioOptica, Milan, Italy) to avoid mucus damage during processing. 
Five-micrometre frozen sections of each sample were cut, and after rinsing in 3% acetic acid 
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(Merck, Germany), the cells were stained with 1% Alcian Blue (Merck, Germany) and 
oxidized in 1% periodic acid (Merck, Germany). Finally, sections were counterstained with 
Mayer's haematoxylin and mounted with Aquamount (BDH, Poole, UK). Measurement of the 
mucus thickness was performed in the middle of the membrane using the ruler tool provided 
by the Zeiss Axio Observer/ApoTome. 
 
3.8 HDAC activity assay  
To assess HDAC activity, HT-29 cells were treated with 10 nmol/L trichostatin A (TSA, 
Sigma-Aldrich) and with butyrate (0.1; 0.5; 0.75; 1; 2 mM) for 48 hours. HT-29 cells nuclear 
extracts (3x107 cells/well in 10 mL of culture medium) were prepared by using the Nuclei EZ 
Prep kit (Sigma-Aldrich) and quantified by with the Micro BCA Protein Assay Kit. HDAC 
activity was measured with the EpiQuik HDAC Activity/Inhibition Assay Kit (Epigentek, 
Farmingdale, NY), according to the manufacturer’s instructions.  
 
3.9 Food allergy animal model 
For all experiments three week-old female C3H/HeJ mice were purchased from Charles River 
Laboratories (Calco, Lecco, Italy). Mice were housed in the animal facility under a 12L:12D 
lighting cycle, 20-24ºC range of ambient temperature and 40-70% of relative humidity. The 
mice were acclimated to their environment for 1 week before experiments. Each experiment 
was littermate controlled and mice were cohoused throughout manipulations. All procedures 
involving the animals were carried out in accordance with the Institutional Guidelines and 
complied with the Italian D.L. no.116 of January 27, 1992 of the Italian Ministry of Health 
and associated guidelines in the European Communities Council Directive of November 24, 
1986 (86/609/ECC) and they were approved by the Institutional Committee on the Ethics of 
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Animal Experiments (CSV) of the University of Naples “Federico II” and by the Ministero 
della Salute (protocol no.2012-0024683). 
 
3.10 Food allergen sensitization and challenge 
The experimental design is reported in Figure 4. Briefly, two weeks prior to sensitization, 
mice were given 30 mg/kg/day of butyrate by oral gavage and continued during the whole 
study. The control animal received only PBS. After 14 days, mice were sensitized orally using 
a blunt needle on day 0, 7, 14, 21, 28 with 20 mg of β-lactoglobulin (BLG) (Sigma-Aldrich, 
Steinheim, Germany) or 1 mg of ovalbumin (OVA) (Sigma-Aldrich, Steinheim, Germany) or 
12 mg of peanut extract (kindly provided by Prof. Nagler)  mixed with 10 µg cholera toxin 
(CT) as adjuvant. The control mice receive CT only.  
One week after the final sensitization, two doses of 50 mg BLG or 5 mg OVA or 36 mg PN 
each were administered via intragastric gavage 30 minutes apart. Core body temperature was 
measured prior to allergen challenge and every 5 minutes after the first challenge until at least 
30 minutes after the second challenge using a rectal probe (Mitutoyo, Lainate, Italy). 
Anaphylaxis symptoms were scored by an investigator blind to the study group assignment 1 
hour after oral challenge, as previously described [16]: 0 = no symptom; 1 = scratching and 
rubbing around the nose and head; 2 = reduced activity; 3 = activity after prodding and 
puffiness around the eyes and mouth; 4 = no activity after prodding, labored respiration, and 
cyanosis around the mouth and the tail; and 5 = death. Serum was collected 1 hour after the 
second challenge to measure mMCP-1 levels. Spleen and serum were collected 24 hours after 
challenge for splenocyte culture and antibody measurements. 
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3.11 ELISAs 
mMCP-1 was quantified in serum collected 1 hour after challenge according to the 
manufacturer’s protocol (eBioscience). BLG/PN-specific ELISAs were performed using 
protocols modified from ref X. Briefly, plates were coated overnight at 4˚C with 100µg/mL 
BLG/PN in 100mM carbonate-bicarbonate buffer (pH 9.6). Plates were blocked for 2 hours at 
room temperature with 3% BSA. Samples were added in 1% BSA and incubated overnight at 
4˚C. Assays were standardized with BLG/PN-specific antibodies (IgE) purified from mice 
immunized with BLG+alum or PN+alum on a CNBr-Sepharose affinity column(X). 
Secondary antibody (biotin-anti-IgE, BD Pharmingen) was added at a 1:500 dilution 
overnight at 4˚C. On the third day, the plate was incubated with streptavidin-HRP 
(ThermoFisher) for 1 hour at room temperature and developed with TMB (Sigma) and 15 min 
were allowed for the development of colorimetric reactions. Absorbance were read at a 
wavelength of 450 nm in a microplate reader. OVA-specific IgE were measured using 
commercially ELISA kit (eBioscience). 
 
3.12 Spleen culture and cytokine measurement 
Single-cell suspensions were prepared from spleens harvested 24 h after challenge. Cells were 
plated at 2×105cells per well with media alone, 1 μg/mL anti-CD3 (clone 2C11), or 200 
μg/mL BLG/OVA/PN and incubated at 37 °C for 72 h. After 72 h, plates were frozen at −20 
°C. IL-4, IL-13, IL-10, and INF-γ concentrations in supernatants were measured using 
commercially ELISA kit (eBioscience). 
 
3.13 Preparation of isolated mitochondria and polarographic measurement of 
respiration 
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After removal, the livers were finely minced and washed in a medium containing 220 mM-
mannitol, 70 mM sucrose, 20 mM -N’-(2-hydroxyethyl)piperazine-N-2-ethanesulfonic acid 
(HEPES) (pH 7.4), 1 mM-EDTA, and 0•1 % (w/v) fatty-acid-free bovine serum albumin 
(BSA). Tissue fragments were homogenised with the above medium (1:4, w/v) in a Potter 
Elvehjem homogeniser (Heidolph, Kelheim, Germany) set at 500 rpm (4 strokes/min). The 
homogenate was centrifuged at 1000 gav for 10 min and the resulting supernatant fraction 
was again centrifuged at 3000 gav for 10 min. The mitochondrial pellet was washed twice and 
finally re-suspended in a medium containing 80 mM-KCl, 50 mM-HEPES (pH 7.0), 5 mM 
KH2PO4, and 0.1% (w/v) fatty-acid-free BSA. The protein content of the mitochondrial 
suspension was determined by the method of Hartree (1972) using BSA as the protein 
standard. Isolated mitochondria were then used for the determination of respiratory 
parameters. Mitochondrial O2 consumption was estimated by a Clark type electrode (Yellow 
Springs Instruments, Yellow Springs, OH, USA), maintained in a water-jacketed chamber at 
30°C. Hepatic mitochondria (0.5 mg protein) were incubated in a medium (3 ml) containing 
80 mM KCl, 50 mM HEPES, 1 mM EGTA, 5 mM KH2PO4 (pH 7.0), and 0.1% (w/v) fatty-
acid-free BSA. The substrates used for liver respiration were 10 mM succinate + 3.75 μM-
rotenone or 40 μM-palmitoyl-carnitine + 2.5 mM-malate for the determination of fatty acid 
oxidation rate. State 3 measurements were performed in the presence of 0.6 mM ADP. State 4 
respiration was measured in the absence of ADP in isolated mitochondria. The ratio between 
state 3 and 4, called the respiratory control ratio, was calculated according to Estabrook 
(1967). 
 
3.14 Determination of mitochondrial enzymatic activities and H2O2 release 
Total activity of the Carnitine Palmitoyl-CoA Transferase (CPT) was followed 
spectrophotometrically as CoA-sH production by the use of 5,5'-dithiobis (nitrobenzoic acid) 
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(DTNB) and as substrate palmitoyl CoA. The medium consisted of 50 mM KCl, 10 mM 
Hepes (pH 7.4), 0.025% Triton X-100, 0.3 mM DTNB, and 10-100 pg of mitochondrial 
protein in a final volume of 1.0 ml. Two cuvettes were used, both containing the same 
medium as that used in the mitochondrial samples. In addition, the sample cuvette contained 1 
mM L-carnitine. The reaction was started by simultaneous addition of acyl-CoA to both 
cuvettes, and the change in absorbance difference between the two cuvettes was followed at 
412 nm. Enzyme activity was calculated from E412 = 13,6OO/(M X cm). The temperature 
was thermostated to 25°C. (Alexson 1988). Mitochondria (40–60 μg) were solubilized in 1% 
Triton X-100. Aconitase specific activity was measured in a medium containing 30 mmol/l 
sodium citrate, 0.6 mmol/l MnCl2, 0.2 mmol/l NADP, 50 mmol/l Tris-HCl, pH 7.4, and 2 
units isocitrate dehydrogenase, and the formation of NADPH was followed 
spectrophotometrically (340 nm) at 25°C. (Hausladen, 1996). The rate of mitochondrial H2O2 
release was measured at 30°C following the linear increase in fluorescence (exicitation at 
320nm, emission at 400 nm) due to oxidation of homovanillic acid by H2O2 in the presence of 
horseradish peroxidase in a computer controlled Jasco fluorometer equipped with a 
thermostatically controlled cell-holder. The reaction mixture consisted of 0.4 mg of 
mitochondrial proteins and succinate (0.6M) added at the end to stat the reaction in the same 
incubation buffer used for measurements of O2 consumption. Known concentrations of H2O2 
were used to establish the standard concentration curve (Barja, 1998). 
3.15 Statistical Analysis 
The Kolmogorov-Smirnov test was used to determine whether variables were normally 
distributed. To evaluate the differences among continuous variables, the independent 
sample t-test was performed.. The level of significance for all statistical tests was 2-sided, p < 
0.05. All analyses were conducted by a statistician, using SPSS version 19.0 for Windows 
(SPSS Inc., Chicago, IL, USA) and Graph Pad Prism 5.0. 
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4. Results 
4.1 Butyrate concentration in human milk 
100 healthy lactating women were consented to participate in the study and provided HM 
samples during the first 5 months of lactation. Butyrate concentrations in colostrum and in 
mature HM are reported in Figure 5. Butyrate concentration resulted significantly higher in 
mature HM than in colostrum starting from the 0.5 to 0.75 mM in the 2 ° month of lactation, 
and remain stable until the 5° month of lactation. This result was in line with previous study 
in which HM has been examined as a potential source of butyrate for neonates (194). Median 
butyrate concentration in mature HM was 0.75 mM. This means that a breastfed infant could 
receive a daily dose of butyrate of about 30 mg/Kg body weight. 
4.2 Effects of butyrate on CD4+ T cells 
To investigate immunological effects of butyrate, we performed time-course and dose 
response experiments on PBMCs from healthy children. Butyrate was able to stimulate IL-10 
production, with a maximal effect at 0.75 mM after 24 hours of incubation. No modulation 
was observed for IL-4, IL-5, IL-13 and IFN-γ production (data not shown). PBMCs from IgE-
mediated FA patients, stimulated with BLG, OVA, PN in absence of butyrate, resulted in a 
significant increase in Th2 cytokines production: IL-4, IL-5 and IL-13. Co-incubating the 
cells with 0.75 mM, butyrate induced a significant inhibition of these effects (Figure 6). This 
effect was independent on a methylation of the promoter region of the IL-4, IL-5 and IL-13 
genes. Instead, butyrate stimulated the tolerogenic cytokines IL-10 and IFN-γ production 
through a demethylation of respective genes at 0.75 mM dose. This effect paralleled with a 
modulation of TSDR FoxP3 demethylation and its expression (Figure 6). 
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4.3. Effects of butyrate on human enterocytes 
The direct regulatory action elicited by butyrate on human enterocytes in the regulation of 
non-immune tolerogenic mechanisms is depicted in Figure 5. Butyrate stimulated the 
expression of tight junction (TJ) proteins, ZO-1 and occludin in Caco-2 cells. The maximal 
effective dose was 0.75 mM. The same butyrate dose was also able to up-regulate Muc2 and 
Muc5AC expression, in HT-29 and Caco-2 cells, respectively (Figure 7). Accordingly, 0.75 
mM butyrate was able to increase the enterocyte mucus layer thickness (from 0.0 to 5±2 µm, 
NT vs 0.75 mM, p<0.05). We also investigated the butyrate effect on the innate immune 
peptide synthesis, HBD-3, that is involved in Foxp3+ T cells induction (195). As shown in 
Figure 7, butyrate elicited a significant effect on HBD-3 synthesis by human enterocytes with 
maximum effective dose of 0.75 mM. 
To determine whether butyrate acts as an HDAC inhibitor in HT-29 cells, we analyzed the 
HDAC activity in comparison with TSA, a well-established HDAC inhibitor. We observed 
that HDAC activity was reduced in a dose-dependent manner in HT-29 cells treated with 
butyrate (Figure 7). 
 
4.4 Effects of butyrate in FA animal model 
BLG-, OVA- and PN- sensitized mice showed a significantly higher anaphylactic symptoms 
score and body temperature decrease, compared to control animals. Exposing the animal to 
oral butyrate caused a significant inhibition of these parameters of allergic response (Figure 
8).  
To determine whether the butyrate administration was effective in reducing local mucosal 
mast cell degranulation in sensitized mice, mMCP-1 serum concentrations were measured 
after oral challenge. Serum mMCP-1 concentration was significantly increased in BLG-, 
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OVA- and PN- sensitized mice compared to the control animals. Whereas, oral butyrate 
caused a significant reduction in mMCP-1 concentration compared to control mice. 
According with these data, butyrate administration also caused a reduction in specific IgE 
concentrations compared to control group (Figure 8). 
To study the mechanism underlying the effect of butyrate in reducing allergic response, 
splenocytes cytokines production was investigated. BLG-, OVA- and PN- sensitized mice 
showed a significant increase in Th2 cytokines production (IL-4 and IL-13) and a significant 
decrease in Th1 cytokines production (IL-10 and IFN-gamma) compared to control animals. 
These effects were significantly inhibited by butyrate administration (Figure 8). 
 
4.5 Effects of butyrate on hepatic mitochondrial oxidative capacity and hepatic oxidative 
stress 
Pivotal role for hepatic mitochondrial dysfunction, and consequent excessive generation of 
ROS,  in a murine model of FA has been recently demonstrated (196). H2O2 yield and ROS-
induced damage on aconitase activity were measured in hepatic mitochondria. The increased 
ROS production was proven by the higher mitochondrial H2O2 yield and the lower basal/total 
aconitase ratio in all sensitized animals when compared to the control group. Butyrate 
administration efficiently modulated the oxidative stress as demonstrated by the lower H2O2 
release and by the reactivation of the aconitase enzyme in all treated groups when compared 
to control animals (Figure 9). 
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5. Discussion  
The results of our study demonstrate that HM butyrate stimulates a wide range of immune and 
non-immune tolerogenic mechanisms able to protect against FA. Immune tolerance is a state 
of active non-responsiveness to ingested soluble antigens mediated by gut-associated 
intestinal lymphoid tissue. Inducible FoxP3+ CD4+ Treg cells are central to the maintenance of 
immune homeostasis and tolerance throughout the body, particularly in the gut. Other 
evidence suggests also a role for the complex interaction between gut microbiota and immune 
and non-immune cells in shaping immune tolerance. The presence of both diet-and microbe-
induced populations of Treg cells is required for oral tolerance to food antigens (197). In our 
study, we observed that butyrate is able to modulate these mechanisms of oral tolerance.  
We evaluated the direct effects of butyrate on CD4+ T cells isolated from PBMCs from 
children affected by challenge-proven IgE-mediated FA. CD4+ T cells were stimulated in 
vitro with different allergens, BLG, PN and OVA, in the presence or absence of butyrate. 
Butyrate stimulated, in a dose-dependent manner, tolerogenic cytokines, such as IL-10 
production, through a demethylation of respective gene. We found also that butyrate induced 
a FoxP3 demethylation and a concomitantly increase of its expression. The mechanisms of 
action of butyrate are multiple, many of these involve an epigenetic regulation of gene 
expression through the inhibition of histone deacetylase (HDAC) (198).  It has been 
demonstrated that the inhibition of HDAC 6 and 9 is responsible for the increase in FoxP3 
gene expression and increase of Tregs (199). Acetylation of Foxp3 is an important 
posttranslational mechanism that affects Foxp3 abundance, because it protects Foxp3 
proteasomal degradation (200). This is a signature mechanism of action of several HDACs in 
Tregs (201-205). 
We also explore the direct effects of butyrate on human enterocytes. Our data suggest that 
SCFA butyrate contribute to mucosal homeostasis through the induction of Treg cells and the 
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regulation of epithelial barrier integrity. Loss of epithelial integrity in the gut increases 
antigen uptake and promotes secretion of epithelial-derived cytokines IL-33, thymic stromal 
lymphopoietin, and IL-25 (206). These cytokines promote Th2-type allergic response by 
activation of ILC2s, mast cells, basophils, and DCs (207). Activation of ILC2s stimulates 
production of IL-4–, IL-5–, and IL-13–promoting Th2-type allergic responses (208). Overall, 
the state of the epithelial barrier is thought to be important for sensitization to food antigens.  
The positive modulation of gut mucosa integrity by butyrate is supported by the up-regulated 
expression of TJ proteins, which in turn are involved in the tuning of epithelial permeability. 
These results are in line with previous observations demonstrating that butyrate is able to 
maintain epithelium barrier integrity through an increase of ZO-1 and occludin expression 
(209).   
A significant increase of Muc2, Muc5AC expression and mucus layer thickness was also 
observed after stimulation of human enterocytes with butyrate. Similarly, Gaudier et al. 
demonstrated that butyrate differently stimulates the expression of various mucin genes in the 
colon, with maximum effects on Muc2 expression (210). The mucus layer, covering the 
gastrointestinal mucosa, is considered as the first line of defense against mechanical, 
chemical, or microbiological aggressions arising from the luminal contents (211). The mucus 
layer does not merely form a nonspecific physical barrier, but also constrains the 
immunogenicity of gut antigens by delivering tolerogenic signals (212). In the colon, the 
mucus layer is directly in contact with the butyrate produced by gut microbiota, representing 
the major energy source for colonocytes (213).  
Moreover, butyrate stimulates the HBD-3 synthesis, an innate immune peptide, involved in 
induction of FoxP3+ T cells (195).  
To confirm the butyrate immune and non immune effects demonstrated in vitro, we 
performed  an in vivo model of FA.  In a murine model of FA, the results of anaphylactic 
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symptom score and body temperature decrease demonstrated that butyrate administration 
inhibits allergic response. Accordingly, butyrate administration caused a significant reduction 
in mMCP-1 concentrations, which reflects a reduction in mast cell degranulation, and a 
reduction in sIgE concentrations compared to control group. 
To study the mechanism underlying the effects of butyrate administration in reducing allergic 
response, cytokine production by T-cells in the spleen was studied and a modulation of 
Th1/Th2 cytokine expression was observed. We found an enhancement in IL-10 expression, a 
major immune-regulatory cytokine that maintains mucosal homeostasis and limits excessive 
immune responses against dietary and bacterial antigens present in the intestinal lumen.  
We found liver mitochondrial dysfunction in FA sensitized mice. After sensitization with 
three antigens, a significant decrease in mitochondrial state 3 respiration rates was observed in 
PN and BLG sensitized animals when compared to control animals, while butyrate 
administration improved mitochondrial respiration rates in treated animals. Instead, butyrate 
administration efficiently modulated the oxidative stress as demonstrated by the lower H2O2 
release and by the reactivation of the aconitase enzyme in all treated mice groups. 
Mitochondrial dysfunction and elevated ROS have been reported in allergic disease (214-
217). The involvement of liver in FA is emerging (218). Studies in a murine model suggest 
that the liver could act as a source of helper CD4+ T cells and could play an important role in 
the IgE response to dietary antigens (219). As demonstrated in the airway epithelium of 
asthma animal model, mitochondrial dysfunction precedes allergic inflammation, where prior 
to antigen exposure, mitochondrial dysfunction exacerbates allergen-induced accumulation of 
eosinophils, mucin levels, and airway hyperresponsiveness (220). 
Interestingly, the most effective butyrate dose is similar to mean butyrate concentration in 
HM. Data generated from Global Exploration of Human Milk (GEHM) study suggests that 
butyrate concentration in HM through the first year of lactation are consistent across regions, 
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but that factors such as maternal diet or microbiome could influence overall levels given 
butyrate’s association with individual donor (221). From the analysis of 3-days dietary diary 
of the lactating mothers, we observed a significant correlation between their daily fiber intake 
and HM butyrate concentration. As more dietary fibers are ingested, SCFAs production 
increases (222). New evidence show that maternal SCFA levels during pregnancy can directly 
influence the health of infants. Thorburn et al. observed that when a high-fiber diet was 
consumed during pregnancy, maternal serum acetate levels were higher (223). Lower serum 
levels of acetate during pregnancy were associated with wheeze in infants. In a follow-up 
murine model experiment, feeding dams acetate during pregnancy and the immediate 
postpartum period reduced the development of allergic airway inflammation in offspring. In 
the field of FA, we know that an infant diet consisting of high levels of fruits, vegetables, and 
home-prepared foods is associated with less FA by the age of 2 years (224). The finding that 
high fiber diet protects mice against peanut allergy through diverse cellular pathways supports 
these data. Tan et al. find that this effect involves reshaping of the gut microbiota as well as 
increased levels of SCFAs and activity of their receptors. High fiber feeding also increased 
tolerogenic CD103+ DCs activity, leading to increased Treg cells differentiation (225). The 
results from our work suggest that the dietary fiber intake of the lactating mothers could 
influence the HM butyrate concentration, with multiple protective effects against FA. This 
could be relevant for future research, because all the observed effects were dose dependent. 
Our data open the possibility of using butyrate as a supplement in the formulas of non-
breastfed children for preventing FA in early life. A limitation of our study is that we are 
unable to determine where the butyrate present in HM derives. Considering that there are 
bacterial species in the HM, we cannot rule out that it derives from these ones or from 
maternal intestinal microbiota. Another limitation of our study is that HM contains a wide 
range of bioactive factors in addition to butyrate: such as proteins, polyunsaturated fatty acids, 
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oligosaccharides, microbial content, metabolites, and micronutrients that can influence the 
infant’s gut immune maturation. 
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6. Conclusion 
Gut microbiota could be a promising target for innovative preventive and therapeutic 
strategies against FA. Studies are promising, but more data are needed to better define the 
potential of modulating the diet-gut microbiota–immune system axis to fight FA. We are 
approaching a new era where we can regulate immune system development and function 
through dietary intervention and measure the clinical impact through gut microbes and their 
metabolites.  Given the current gaps in the investigational approaches, and data analysis and 
interpretation, we need more scientific evidence that can be translated in clinical practice. 
Understanding how nutrients and metabolites, or probiotics could influence gut bacteria 
communities and the immune system will contribute to build up a precision medicine 
approach for FA care (Figure 10). 
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8. Tables and Figures  
 
 
Table 1: Main gut microbiota features in food allergy  
 
 
 
Abbreviations: FA= food allergy; FS= sensitization to food antigens; OTUs = operational taxonomic units; 
N.R.= not reported 
 
 OTUs DIVERSITY TECHNOLOGY MAIN FEATURES REFERENCES 
Byorkesten et al. 
1999 (n=62; FA) 
N.R. N.R. Bacterial culture  Coliforms, S. Aureus 
Lactobacilli,  Bifidobacteria 
226 
 
Thompson-Chagoyan 
OC et al. 2010 
(n=46:FA) 
 N.R. Bacterial culture  Lactobacilli 
 Bifidobacteria 
227 
Thompson-Chagoyan 
OC et al. 2011 
(n=46:FA)  
N.R. N.R. Bacterial culture C.coccoides, Atophium cluster  228 
Nakayama J et al. 
2011 (n=11: FA)  
 
= 
 
= 
 
16s rRNA 
sequencing 
 
Bacteroides,Propionibacterium 
, 
 Klebsiella 
Acinobacterium, Clostridium  
229 
Ling Z et al. 2014 
(n=34: FA)  
 
 = 
 
16s rRNA 
sequencing 
Bacteroidetes, Proteobacteria, 
Actinobacteria 
 Firmicutes 
230 
Azad MB et al. 2015 
(n=12: FS)  
 
 = 
 
16s rRNA 
sequencing 
 Enterobacteriaceae, 
Bacteroidaceae 
45 
Chen CC et al. 2015 
(n=23: FS)  
 
N.R. 
 
 16s rRNA 
sequencing 
Firmicutes, Proteobacteria, 
Actinobacteria 
Veillonella 
231 
Berni Canani et al. 
2016 (n=39; FA) 
 
 
N.R. 
 
16s rRNA 
sequencing 
Ruminococcaceae, 
Lachnospiraceae 
Bifidobacteriaceae, 
Streptococcaceae, 
Enterobacteriaceae 
43 
Bunyavanich S.et 
al.2016 (n=226; FA) 
 N.R. 16s rRNA 
sequencing 
Bacteroidetes, Enterobacter 46 
Inoue R et al. 2017 
(n=4: FA)  
 
N.R. 
 
N.R. 
 
16s rRNA 
sequencing 
Lachnospira, Veillionella, 
Suterella 
Dorea, Akkermansia 
232 
Kourosh A. et al. 
2018 (n=68; FA) 
 N.R. 16s rRNA 
sequencing 
Oscillobacter valericigenes, 
 Lachnocrostidium bolteae, 
Faecalibacterium sp.  
233 
Fazlollahi M. et 
al.2018 (n=141; FA) 
N.R. N.R. 16s rRNA 
sequencing 
Lachnospiraceae, 
Streptococcaceae,    
Leuconostocaceae 
234 
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Table 2. Main preclinical evidences on the probiotics role against food allergy 
Biological effects Bacterial strains References  
Intestinal Barrier Maturation B. lactis/bifidum; L. rhamnosus GG 123,125, 235, 
Th1/Th2 response balance: Th1 stimulation B.lactis/bifidum/ infantis; L. acidophilus/reuteri; 
L.rhamnosus GG 
127,128,236 
Th1/Th2 response balance: Th2 suppression B. bifidum/infantis/longum;L.actobacillus 
acidophilus/reuteri; L.rhamnosus GG 
 
127,129, 130,132,133 
Immune system regulation: Tregs development B.bifidum/infantis/lactis;L.acidophilus/reuteri/casei;L. 
rhamnosus GG 
235,236 
Increase in B and T cell proliferation with 
enhanced production of Th1 and regulatory 
cytokines 
L.acidophilus;L. casei;L.salivarius;L.lactis;B. infantis; B. 
lactis; B. longum 
133 
Immune system regulation: tolerogenic DCs 
development 
B.bifidum;L.reuteri/casei; L.rhamnosus GG 237, 238 
Suppression of IgE production B. bifidum/longum; B.lactis Bb-12; L.acidophilus; 
L.rhamnosus GG 
 239,240 
Epigenetic modulation of Th1/Th2 genes 
expression 
B.breve;L. rhamnosus GG 134 
Increase in the production of the regulatory 
cytokine IL-10 by monocytes and dendritic cells; 
enhance of IFN-γ production by T cells 
L. plantarum;B. adolescentis 130,131, 132 
Increase in the population of CD4+FoxP3+ T cells, 
up-regulation of FoxP3 and down-regulation of 
GATA-3  
L.plantarum;B. coagulans 135 
Reduction of allergic reaction; reduction of IL-4, 
IL-5, IL-13 and specific IgE production 
L. rhamnosus GG 140 
Improvement of anaphylaxis symptoms and 
increase of sIgA and CD4+ CD25+ FoxP3Treg 
cell 
C.butyricum 136 
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Figure Legends 
Figure 1. The food allergy pyramid  
Children with FA present an increased risk to develop later in the life other conditions such as 
allergic disorders (atopic march), inflammatory bowel diseases (IBD), functional 
gastrointestinal disorders (FGIDs), and neuropsychiatric disorders. Several genetic factors are 
implicated in the pathogenesis of these conditions, but recent evidence suggest the pivotal role 
of gut microbiota dysbiosis (induced by environmental factors). Emerging evidence support 
the hypothesis of dysbiosis as the first hit in the development of alterations in intestinal 
barrier and immune system function (responsible for the occurrence of FA and atopic march) 
and dysregulation of the brain-gut endocrine-immune system axis (responsible for the 
occurrence of FGIDs, IBD and neuropsychiatric disorders), at least in part through an 
activation of epigenetic mechanisms.  
 
Figure 2. Gut microbiota as a target of intervention against food allergy  
Several genetic, environmental and dietary factors could modulate the gut microbiota-immune 
system axis influencing the occurrence of FA. For instance, increased family size, exposure to 
pets and/or rural environment, healthy diet (full of fibers, fermented foods, antioxidants, 
omega-3), breastfeeding and use of probiotics are associated with protection to FA. 
Conversely, C-section, prenatal and early-life exposure to antibiotics/gastric acidity 
inhibitors/antiseptic agents, unhealthy diet (low fibers/high saturated fats and junk foods) may 
increase the risk for the development of FA. All these environmental factors act mainly on a 
modulation of gut microbiota composition and function which in turn could be responsible for 
the epigenetic regulation of genes involved in immune tolerance.  
 
Figure 3. The structure of the gut microbiota-immune system axis  
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Within the gut microbiota-immune system axis the cross talk between microbes and the 
immune system may occur directly through microbial components or indirectly through the 
action of metabolites, such as SCFAs. A positive modulation of this axis can counteract the 
pathogenesis of FA by promoting epithelial integrity, gut permeability, mucus production, 
CD103+ tolerogenic DCs, Treg differentiation, cytokines production and sIgA release from 
plasma cells.  
 
Figure 4. The experimental design of food allergy mouse model 
Four-weeks-old female C3H/HeJ mice were used in FA animal model. Two weeks before first 
sensitization, oral gavage with 30 mg/kg/d of butyrate was started and continued during the 
whole study. Mice were sensitized orally on day 0, 7, 14, 21, 28 with 20 mg of BLG or 1 mg 
of OVA or 12 mg of PE mixed with 10 µg cholera toxin (CT) as adjuvant. Control mice 
receive CT only. On day 35 mice were challenged by gavage with BLG (50mg) or OVA 
(5mg) or PE (36mg). Anaphylaxis score and rectal temperature were assessed for 1 h after 
challenge and blood samples were collected to measure mMCP-1 and sIgE. After 24h, mice 
were sacrificed; colon, ileum and spleen were collected. 
 
Figure 5. Butyrate breast milk concentrations during first 5 months of lactaction.  
(A) butyrate concentrations increase in mature HM compared to colostrum.  
(B) resulted significantly higher in mature HM than in colostrum starting from the 0.5 to 0.75 
mM in the 2 ° month of lactation, and remain stable until the 5° month of lactation. Data were 
analyzed with independent sample t-test. *p<0.05. 
 
Figure 6. Modulation of Th1 /Th2 response and FoxP3 expression in PMBCs and CD4+T 
cells from children affected by food allergy stimulated with butyrate  
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PBMCs from children with IgE-mediated FA were stimulated with BLG, OVA,PN (100 
µl/well) and butyrate (0.75 mM) for 24h and  a significant increase of IL-4,IL-5, IL-13 
production were observed. A significant inhibition of IL-4, IL-5 and IL-13 production was 
observed with 0.75 mM butyrate. Butyrate stimulated, at the some dose, IL-10 and IFN-γ  
production and FoxP3 expression,  through a demethylation of respective gene. Data were 
analyzed with independent sample t-test. NT= untreated cells; BLG= β-lactoglobulin; OVA=  
ovalbumin; PN = peanut extract. *p<0.05; **p<0.01. 
 
Figure 7. Immune and non immune effects and HDAC activity of butyrate effects on 
human enterocytes. 
Dose-response direct effects of butyrate on HBD-3, Muc5AC, Muc2 and tight junctions 
expression levels on HT-29 cells. Butyrate acts as an HDAC inhibitor in a dose-dependent 
manner. Data represent the mean (± standard deviation; represented by vertical bars) of two 
independent experiments, each performed in triplicate; Data were analyzed with independent 
sample t-test. HBD-3= β-defensin 3; Muc5AC=mucin 5AC; Muc2=mucin 2; ZO-1= zonula 
occludens 1; GUS = glucuronidase; TSA=trichostatin A. *p<0.05; **p<0.001vs untreated 
cells. 
 
Figure 8. Evidence on effective sensitization to food allergy in the animal model and Th2 
and Th1 response in spleen from mice sensitized to food allergens.  
Pre-treatment with 30 mg/kg/day of butyrate in a BLG-, OVA-, PN- sensitized mice 
significantly reduced anaphylactic score, serum MCP-1 and sIgE levels.  
Cells from spleen were stimulated 1 μg/mL anti-CD3 (clone 2C11), or 200 μg/mL 
BLG/OVA/PN and incubated at 37 °C for 72 h. Butyrate stimulated  IL-10  and IFN-γ (E) 
production and inhibited IL-4 and IL-13 production in BLG-, OVA-, PN- sensitized mice. 
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Data are reported as means ± SEM from duplicate analyses. Data were analyzed with 
independent sample t-test. CTRL= control mice; BLG= mice sensitized with β-lactoglobulin; 
OVA= mice sensitized with ovalbumin; PN = mice sensitized with peanut extract. *p<0.05; 
**p<0.01; ***p<0.001 
 
Figure 9. Evidence of hepatic mitochondrial dysfunction in mice sensitized to food 
allergens.  
 The mitochondrial H2O2 yield and the basal activity of the aconitase were reported. Data are 
reported as means ± SEM from duplicate analyses. Data were analyzed with independent 
sample t-test. Control = control mice; BLG= mice sensitized with β-lactoglobulin; OVA= 
mice sensitized with ovalbumin; PN = mice sensitized with peanut extract.  * p<0.05 vs 
control;# p<0.05 vs sensitized group. 
 
Figure 10. Toward a gut microbiota-based precision medicine against food allergy  
We are approaching an era where the metagenomic and metabolomic evaluation of gut 
microbiota in children at risk for FA will drive personalized intervention to preserve or restore 
an “eubiosis” state based on nutritional counseling and educational programs.  
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